Published in AIDS Weekly, August 24th, 1998
The vaccine, dubbed TBC-3B by manufacturer Therion Biologics Corp., expresses the HIV env, gag, and pol genes. The trial enrolled 36 HIV negative volunteers who received the vaccine (or vaccinia placebo) either via scarification, intradermal injection, or subcutaneous injection.
"TBC-3B administered by [the various routes] to vaccinia-naive, HIV negative volunteers is well tolerated, even when given as a 100 times higher dose boost," reported Michael C. Keefer of the National Institutes of Health.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.